Skip to content6
60 Degrees Pharmaceuticals, Inc.
6
SXTPW60 Degrees Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue$207.90K$207.90K+106.0% vs Q2 2025 Net Income-$2.26M-$2.26MN/M vs Q2 2025 EPS Diluted-$0.90-$0.90N/M vs Q2 2025 Gross Profit$56,798+11.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
60 Degrees Pharmaceuticals, Inc. · CIK 1946563 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,231,721N/M Free Cash Flowderived-$2,231,721N/M Margins · derivedGross margin27.3%−23.1 pt vs Q2 2025
Operating margin-1092.4%+499.1 pt vs Q2 2025
Net margin-1089.2%+628.5 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end